Cancer types
  • Sarcomas
Title of study
International prospective registry on local treatment approaches in myxoid liposarcomas
Version Number
Approval Date 
2, 23 December 2020
Short Title
DO-RE-MY Registry
Study site
Principle Investigator
J. Lansu
Investigator Maastro
P. van den Ende
Sponsor
NKI-AVL
Trial registry
Objectives 

To confirm the promising results of the 36 Gy dose level in the DOREMY trial (NCT02106312) and to compare outcome with other local treatment approaches.

Primary Endpoint 

Local recurrence free survival [Time Frame: From surgery to the end of at least 5 years of follow-up] Survival from surgery to local recurrence (event) or last follow-up.

Secondary Endpoints 

• Wound complications [ Time Frame: From surgery to 6 months of follow-up] Any wound complication requiring intervention
• Late toxicity [ Time Frame: From 3 months after surgery to the end of at least 5 years of follow-up ] Any grade ≥2 late (radiation-induced) toxicity according to RTOG toxicity criteria.

X